Chronoscale Corp

Chronoscale Corp(CHRN)股票分析

$18.740

-1.803 (-9.62%)收盘时

Loading chart…
High
22.220
Open
21.540
VWAP
19.83
Vol
205.17K
Mkt Cap
Low
18.540
Amount
4.07M
EV/EBITDA, TTM
0.00

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. It assists people to perform challenging repetitive tasks for extended periods.

AI analysis of Chronoscale Corp (CHRN)

sell

Ekso Bionics Holdings, Inc. is not a good buy right now due to its poor technical indicators and financial performance. The current price is $18.74, and the RSI is at a low 21.568, indicating oversold conditions. Additionally, the company has a significant forward P/E ratio of 0, reflecting no earnings expectations, and a gross margin of only 50.16%, which is declining. The main risk is the recent 5-day price change of -21.41%, suggesting strong downward momentum.

估值指标

The current forward P/E ratio for Chronoscale Corp (CHRN) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E
Current P/E
0.00

Forward EV/EBITDA

5Y Average EV/EBITDA
Current EV/EBITDA
0.00

Forward P/S

5Y Average P/S
Current P/S
0.00

Whales holding CHRN

A

Applied Digital Corporation

+ HoldingCHRN

-15.55%

3M Return

事件时间线

2026-08-27 (ET)

08:30:00

ChronoScale Partners with Microsoft for 50-Megawatt AI Compute Deployment

2026-07-21 (ET)

12:30:00

ChronoScale Shares Drop 10.7% to $25.81

2026-07-16 (ET)

12:30:00

ChronoScale Shares Drop 19.5% to $23.85

10:30:00

ChronoScale Shares Drop 18.5% to $24.15

2026-07-14 (ET)

12:30:00

ChronoScale Stock Rises 13.2% to $22.32

资讯

CHRN FAQ — answered by Alphio AI

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. It assists people to perform challenging repetitive tasks for extended periods. It operates in the Healthcare sector.

Ekso Bionics Holdings, Inc. is not a good buy right now due to its poor technical indicators and financial performance. The current price is $18.74, and the RSI is at a low 21.568, indicating oversold conditions. Additionally, the company has a significant forward P/E ratio of 0, reflecting no earnings expectations, and a gross margin of only 50.16%, which is declining. The main risk is the recent 5-day price change of -21.41%, suggesting strong downward momentum.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始